Mesoblast Showcased at ASX Premier Investor Day Event
Mesoblast Posts $115 Million in Revenue, Sets Sights on 2027 Back Pain Trial Readout
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
Mesoblast Board Changes
Ryoncil Growth Could Change The Case For Mesoblast Stock
Inside Biotech: Mesoblast surges 24% as Ryoncil sales climb and cash spend falls sharply
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
Mesoblast Receives FDA Approval To Implement A New Potency Assay, T-Cell Proliferation Inhibition Bioassay, For Release And Stability Monitoring Of All New Commercial Product Lots Of Its Mesenchymal Stromal Cell Product Ryoncil
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39
Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Mesoblast Reports Substantial Revenue Growth to US$120M
Mesoblast H2 Earnings Call Highlights
Full Transcript: Mesoblast FY 2026 Earnings Call
Mesoblast Financial Results and Corporate Update Webcast
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.